Is Charles River Laboratories Stock Underperforming the Dow?

With a market cap of $9.5 billion, Charles River Laboratories International, Inc. (CRL) is a leading American contract research organisation (CRO) serving the pharmaceutical, biotechnology, government and academic sectors. The Wilmington, Massachusetts-based company provides preclinical and early-stage drug discovery, safety assessment, and laboratory services that support the development of new drugs, vaccines and medical devices. 

Companies worth between $2 billion and $10 billion are generally described as "mid-cap stocks." CRL fits right into that category. It benefits from a strong competitive position driven by its end-to-end preclinical drug development capabilities, market leadership in research models, and deep, long-standing relationships with pharmaceutical and biotech clients. Its global scale, regulatory expertise, and specialized scientific infrastructure create high barriers to entry and significant switching costs, supporting recurring revenues and customer retention.